Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
1AI | Sydney | AUD | Delayed | |
LVCLY | OTC Markets | USD | Delayed | |
LHI0 | Frankfurt | EUR | Delayed |
Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson’s disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson’s disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer’s disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. The company was founded in 1987 and is based in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Carolyn M. Sue | 60 | 2019 | Member of Medical Advisory Board & Chief Medical Officer of NTCELL |
Bradley John Dilkes | 38 | 2022 | Non-executive Director |
David Richard Hainsworth | 50 | 2022 | CEO & Executive Chairman |
Bradley R. Latham | 61 | 2023 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review